Viatris reports $3.5B Q1 revenue, 8% growth, $176M net earnings, and reaffirms 2026 guidance.

Viatris Inc. announced strong Q1 2026 results with total revenues of $3.5 billion, up 8% year-over-year, driven by growth in Greater China and new product launches. The company posted a net earnings of $176 million, a significant turnaround from a loss in Q1 2025, and adjusted EBITDA rose 10% operationally. Viatris also launched Effexor for generalized anxiety disorder in Japan and expects to generate over $2.5 billion in cash for deployment in 2026. The company reaffirmed its 2026 financial guidance, signaling confidence in sustained growth and cash flow generation.